Global Artificial Intelligence in Drug Discovery Market

Artificial intelligence (AI) is increasingly utilised in drug discovery to tackle challenges that have hitherto been difficult to solve, such as predicting properties, designing molecules, and optimising synthetic routes. AI can recognize hit and lead compounds, and provide a quicker validation of the drug target and optimization of the drug structure design. The global artificial intelligence in drug discovery market was estimated at USD 991 million in 2022 and is expected to hit USD 4,673 million by 2029, registering a CAGR of 24.8% from 2023 to 2029 as per the latest market estimates.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global artificial intelligence in drug discovery market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the application, therapeutic space, end user, and region. The global market for artificial intelligence in drug discovery can be segmented by application: drug design, optimization and repurposing, preclinical and clinical testing, target identification, others. Among these, the drug design, optimization and repurposing segment was accounted for the highest revenue generator in 2022. Artificial intelligence in drug discovery market is further segmented by therapeutic space: cardiovascular diseases (CVD), infectious disease, metabolic diseases, neurological disorders, oncology, respiratory diseases, others. The oncology segment is estimated to account for the largest share of the global artificial intelligence in drug discovery market. Based on end user, the artificial intelligence in drug discovery market is segmented into: academia and research institutes, contract research organizations (CROs), pharmaceutical and biotechnology companies. The pharmaceutical and biotechnology companies segment held the largest share of the global artificial intelligence in drug discovery market in 2022 and is anticipated to hold its share during the forecast period. On the basis of region, the artificial intelligence in drug discovery market also can be divided into: Asia-Pacific, Europe, North America, Middle East and Africa (MEA), South America. In 2022, North America made up the largest share of revenue generated by the artificial intelligence in drug discovery market.

Market Segmentation
By application: drug design, optimization and repurposing, preclinical and clinical testing, target identification, others
By therapeutic space: cardiovascular diseases (CVD), infectious disease, metabolic diseases, neurological disorders, oncology, respiratory diseases, others
By end user: academia and research institutes, contract research organizations (CROs), pharmaceutical and biotechnology companies
By region: Asia-Pacific, Europe, North America, Middle East and Africa (MEA), South America

The market research report covers the analysis of key stake holders of the global artificial intelligence in drug discovery market. Some of the leading players profiled in the report include Atomwise Inc., Accutar Biotechnology Inc., Ardigen S.A., BenevolentAI Limited, Berg LLC, Berkeley Lights, Inc., BioAge Labs, Inc., BioSymetrics Inc, Biovista Inc., C4X Discovery Holdings plc, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason Ltd., Deep Genomics Incorporated, DeepThink Health, Inc., Envisagenics, Inc., e-therapeutics plc, Euretos Services BV, Exscientia plc, GNS Healthcare Inc., Insilico Medicine Inc, Lantern Pharma Inc., NuMedii, Inc., Nuritas, Ltd., Owkin, Inc, Recursion Pharmaceuticals, Inc., Schrodinger, Inc., Symphony Innovation LLC, TARA Biosystems, Inc. (Valo Health, LLC), twoXAR, Inc. dba Aria Pharmaceuticals, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
• To analyze and forecast the market size of the global artificial intelligence in drug discovery market.
• To classify and forecast the global artificial intelligence in drug discovery market based on application, therapeutic space, end user, region.
• To identify drivers and challenges for the global artificial intelligence in drug discovery market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global artificial intelligence in drug discovery market.
• To identify and analyze the profile of leading players operating in the global artificial intelligence in drug discovery market.

Why Choose This Report
• Gain a reliable outlook of the global artificial intelligence in drug discovery market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Global Artificial Intelligence in Drug Discovery Market

Interested in this report? Get your FREE sample now!
Global Artificial Intelligence in Drug Discovery Market - Report Scope
REPORT ATTRIBUTE

DETAILS

Base Year

2022

Forecast Year

2023-2029

CAGR (2023-2029)

24.8%

Pages

94

Key Players

Atomwise Inc., Accutar Biotechnology Inc., Ardigen S.A., BenevolentAI Limited, Berg LLC, Berkeley Lights Inc., BioAge Labs Inc., BioSymetrics Inc, Biovista Inc., C4X Discovery Holdings plc, Cloud Pharmaceuticals Inc., Cyclica Inc., CytoReason Ltd., Deep Genomics Incorporated, DeepThink Health Inc., Envisagenics Inc., e-therapeutics plc, Euretos Services BV, Exscientia plc, GNS Healthcare Inc., Insilico Medicine Inc, Lantern Pharma Inc., NuMedii Inc., Nuritas Ltd., Owkin Inc, Recursion Pharmaceuticals Inc., Schrodinger Inc., Symphony Innovation LLC, TARA Biosystems Inc. (Valo Health LLC), twoXAR Inc. dba Aria Pharmaceuticals

Related Reports

$2,950.00

Want to customize this report?
The present report possesses the flexibility to be tailored to your specific needs. Our team of analysts and industry experts will collaborate directly with you to gain a comprehensive understanding of your requirements.
Scroll to Top

Download Free Sample - Global Artificial Intelligence in Drug Discovery Market

Please fill out our form and we will get back to you.